Paper Details

  1. Home
  2. Paper Details

Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?

Author: AkutaNorio, AraseYasuji, HosakaTetsuya, IkedaKenji, KawamuraYusuke, KobayashiMariko, KobayashiMasahiro, KumadaHiromitsu, MiyakawaYuzo, SaitohSatoshi, SezakiHitomi, SuzukiFumitaka, SuzukiYoshiyuki, YatsujiHiromi

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Entecavir in the long term would be useful for histological improvement of breakthrough hepatitis induced by lamivudine-resistant HBV mutants in patients with chronic hepatitis B. However, the relatively high rate of entecavir resistance is a concern.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND AIMS: Long-term lamivudine therapy is required for patients with chronic hepatitis B, because hepatitis reappears frequently after it has withdrawn. However, hepatitis B virus (HBV) mutants resistant to lamivudine emerge frequently accompanied by breakthrough hepatitis. METHODS: Effe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1440-1746.2008.05760.x

データ提供：米国国立医学図書館（NLM）

Fighting Hepatitis B: Entecavir's Effectiveness

Hepatitis B, a stubborn adversary in the desert of human health, is a persistent threat. This study delves into the effectiveness of entecavir, a drug used to treat chronic hepatitis B, particularly in cases where the virus has become resistant to lamivudine, a common treatment. It's like finding a new weapon in the fight against a persistent enemy, a weapon that can overcome resistance and restore balance.

Entecavir: A New Weapon in the Fight

The study found that entecavir can effectively suppress the hepatitis B virus and improve liver health, even in patients with lamivudine-resistant strains. While entecavir showed promising results, the emergence of entecavir-resistant strains remains a concern. It's like facing a formidable enemy that can adapt and evolve, demanding a constant search for new strategies. The study reminds us that the battle against hepatitis B is ongoing, requiring continuous vigilance and adaptation.

Staying Ahead in the Hepatitis B Desert

This research underscores the importance of ongoing research and development in the fight against hepatitis B. It's like carefully navigating a desert, where new challenges and obstacles arise constantly. The study highlights the need for new strategies and treatments, reminding us that the quest for a cure for hepatitis B is far from over. We must continue our journey, seeking new weapons to fight this persistent enemy.

Dr.Camel's Conclusion

Hepatitis B is a formidable foe, a persistent desert wind that can wreak havoc on our health. This study, like a beacon of hope in the desert, shows us the potential of entecavir in combating this disease. However, the emergence of resistance highlights the need for continued research and development. We must remain vigilant and adapt our strategies, striving for a day when hepatitis B is nothing more than a distant sandstorm in our medical memory.
Date :
  1. Date Completed 2009-06-25
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

19226381

DOI: Digital Object Identifier

10.1111/j.1440-1746.2008.05760.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.